ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL ... It is the most common form of non-Hodgkin lymphoma (NHL), accounting for ...

As Memorial Day weekend marks the unofficial start to summer, the Surfrider Foundation is releasing its annual Clean Water Report to help keep you and your family safe at the beach. This comprehensive ...

The global Burn Care Market is projected to be valued at USD 2.79 billion in 2024 and reach US$ 4.23 billion by 2030, growing at a CAGR of 7.18% according to a new report by The Research Insights. The ...

Being diagnosed with cancer is one of the scariest things imaginable. But a cancer diagnosis doesn't have to be a death ...

Most clinical trials test new treatments only after cancer has relapsed and grown large enough to be detected on scans. The ...

Early melanoma diagnosis is critical, with a 99% 5-year survival rate if detected early, dropping to 35% if metastasized. A ...

New global analysis calls for urgent, targeted interventions as aging populations face rising rates of skin cancer.

The incidence of early-onset cancers is not rising overall, but rates of certain cancers are increasing among younger patients, new data suggest.

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC ... Kaplan-Meier estimates of OS and PFS in the (A and E) ITT population, (B and F) patients with ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...